Skip to main
ZYME

Zymeworks Inc (ZYME) Stock Forecast & Price Target

Zymeworks Inc (ZYME) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Zymeworks is a clinical-stage biopharmaceutical company with a promising suite of therapeutic platforms and a diversified pipeline in oncology and other therapeutic areas, including its HER2-targeted bispecific antibody zanidatamab. With a total firm value of $3.8B and a number of ongoing clinical trials, including the recently FDA-approved zanidatamab in 1L GEA, Zymeworks is poised for potential long-term success. However, risks such as clinical trial failures, competition, regulatory uncertainty, and industry trends should be considered when evaluating this investment opportunity.

Bears say

Zymeworks is facing multiple challenges as a clinical-stage biopharmaceutical company, including lower than estimated revenues and higher than anticipated expenses. The recent acquisitions have resulted in the impairment of acquired IPR&D, and the company heavily relies on partnerships for commercial success, increasing its marketing risk. Furthermore, the company's sole asset YUPELRI faces competition and potential generic entrants, and its pipeline products are not yet approved by any regulatory body, posing regulatory risks. The company has low cash flow and limited pipeline optionality, leading to financial risk and a potential sale.

Zymeworks Inc (ZYME) has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Zymeworks Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Zymeworks Inc (ZYME) Forecast

Analysts have given Zymeworks Inc (ZYME) a Buy based on their latest research and market trends.

According to 10 analysts, Zymeworks Inc (ZYME) has a Buy consensus rating as of Sep 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42.70, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42.70, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Zymeworks Inc (ZYME)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.